Idorsia Ltd. is a biopharmaceutical company that engages in the discovery, development, and commercialization of innovative medicines. Its primary purpose is to transform patient care through novel th... Idorsia Ltd. is a biopharmaceutical company that engages in the discovery, development, and commercialization of innovative medicines. Its primary purpose is to transform patient care through novel therapeutic solutions. Focusing on high unmet medical needs, Idorsia targets areas such as insomnia, hypertension, and rare diseases, aiming to bring breakthrough treatments to market. With a rich pipeline that spans various phases of clinical trials, the company reflects a strong commitment to research and development.
Idorsia's diverse drug portfolio positions it as a significant player in the healthcare industry, particularly within the pharmaceuticals and biotechnology sectors. The company, founded in 2017 and headquartered in Allschwil, Switzerland, emerged from Johnson & Johnson’s acquisition of Actelion, emphasizing its robust scientific heritage and ambition for forward-looking innovation.
In the financial markets, Idorsia Ltd. is recognized for its potential to influence therapeutic paradigms, focusing not only on the creation of new medicines but also on ensuring they reach patients in need globally. With a forward-thinking approach, Idorsia aims to contribute meaningfully to the advancement of medical science and patient health outcomes.
Pending data availability
Waste Management Data missing for Idorsia
We haven’t collected Waste Management data for Idorsia yet, or the company
hasn’t made it publicly available.